Comparative Pharmacology
Head-to-head clinical analysis: JENLOGA versus OVCON 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENLOGA versus OVCON 35.
JENLOGA vs OVCON-35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
350 mg orally once daily with food.
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
None Documented
None Documented
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Category C
Category C
Oral Contraceptive
Oral Contraceptive